LRI Board Member Leads Clinical Trial Researching Potential Lupus Treatment
Monday, September 30, 2013
LRI Board member Dr. Daniel Wallace will be leading a clinical trial of a potential treatment for lupus. The drug, milatuzumab, is being developed by the biopharmaceutical company Immunomedics, Inc. Conducted at Cedars Sinai Medical Center in Los Angeles, the trial will recruit approximately 30 lupus patients.
For mor information click here http://www.immunomedics.com/pdfs/news/2013/pr09302013a.pdf
On the go?
Text INFO to 50555 and opt-in to receive breaking news about lupus on your mobile phone.
Message and Data Rates May Apply. Text STOP to 50555 to STOP. Text HELP to 50555 for HELP. Full Terms